{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T06:13:15Z","timestamp":1788415995399,"version":"build-2803163510"},"reference-count":53,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["226141\/Z\/22\/Z, 226130\/Z\/22\/Z, DEL-22-012"],"award-info":[{"award-number":["226141\/Z\/22\/Z, 226130\/Z\/22\/Z, DEL-22-012"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>SARS-CoV-2 has been deprioritized post-pandemic, especially in Africa. Vaccination in Kenya was conducted using the Wuhan-based vaccines only, which showed reduced neutralization efficacy against Omicron and its sublineages.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed SARS-CoV-2 immune surveillance in five health facilities within the Kilifi Health Demographic and Surveillance System from November 2024 to March 2026. Patients in the facilities presenting acute respiratory symptoms were recruited and nasopharyngeal\/oropharyngeal swabs taken for SARS-CoV-2 RT-PCR. Convalescent plasma from 30 patients with confirmed SARS-CoV-2 RT-PCR positive tests and genome sequences were taken for sero-neutralization assays against the infecting variants LF.7, MV.1, and globally predominant strains, XEC.4, LP.8.1 and XFG.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In total 5115 patients were tested and 171 patients (3.4%) were positive for SARS-CoV-2. Cough (91.7%), nasal discharge (74.5%) and fever (55.4%) were the most common symptoms while wheezing (2%) and crackles (2.8%) were rarest.  Sequencing revealed circulation of JN.1 omicron sub-lineages, LF.7, MV.1 and XEF. Sera from majority of individuals infected by the dominant variants, LF.7 and MV.1 were able to neutralize infecting variants but not the recently circulating XFG variant 23% (7\/30) suggesting that infection with a JN.1 lineage virus alone is not sufficient to prevent re-infection with XFG. Overlapping titer distributions was observed between vaccinated and unvaccinated sera, with no statistically significant difference observed for any variant.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our study demonstrates that SARS-CoV-2 continues to circulate in coastal Kenya causing predominantly mild upper respiratory illness while evolution enabling immune escape. These findings emphasize the importance of integrated genomic and immunological surveillance to track emerging variants, evaluate population-level protection, and inform future vaccine update strategies and public health preparedness efforts.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcimb.2026.1910106","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T05:21:33Z","timestamp":1788412893000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Integrated surveillance in Kilifi reveals continued SARS-CoV-2 circulation and immune escape of emerging JN.1 sublineages post-pandemic"],"prefix":"10.3389","volume":"16","author":[{"given":"Gloria","family":"Konyino","sequence":"first","affiliation":[{"name":"KEMRI-Wellcome Trust Research Programme, Center for Geographic Medicine Research, Coast","place":["Kilifi, Kilifi County, Kenya"]},{"name":"Jomo Kenyatta University of Agriculture and Technology","place":["Nairobi, Kenya"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernadette","family":"Kutima","sequence":"additional","affiliation":[{"name":"KEMRI-Wellcome Trust Research Programme, Center for Geographic Medicine Research, Coast","place":["Kilifi, Kilifi County, Kenya"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Owuor","sequence":"additional","affiliation":[{"name":"KEMRI-Wellcome Trust Research Programme, Center for Geographic Medicine Research, Coast","place":["Kilifi, Kilifi County, Kenya"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donwilliams","family":"Omuoyo","sequence":"additional","affiliation":[{"name":"KEMRI-Wellcome Trust Research Programme, Center for Geographic Medicine Research, Coast","place":["Kilifi, Kilifi County, Kenya"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Waweru","sequence":"additional","affiliation":[{"name":"KEMRI-Wellcome Trust Research Programme, Center for Geographic Medicine Research, Coast","place":["Kilifi, Kilifi County, Kenya"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor Andrade","family":"Santos","sequence":"additional","affiliation":[{"name":"Viral Glycoproteins Group, The Pirbright Institute","place":["Pirbright, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnold W.","family":"Lambisia","sequence":"additional","affiliation":[{"name":"KEMRI-Wellcome Trust Research Programme, Center for Geographic Medicine Research, Coast","place":["Kilifi, Kilifi County, Kenya"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther Nyadzua","family":"Katama","sequence":"additional","affiliation":[{"name":"KEMRI-Wellcome Trust Research Programme, Center for Geographic Medicine Research, Coast","place":["Kilifi, Kilifi County, Kenya"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Maina","sequence":"additional","affiliation":[{"name":"KEMRI-Wellcome Trust Research Programme, Center for Geographic Medicine Research, Coast","place":["Kilifi, Kilifi County, Kenya"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyce Uche","family":"Nyiro","sequence":"additional","affiliation":[{"name":"KEMRI-Wellcome Trust Research Programme, Center for Geographic Medicine Research, Coast","place":["Kilifi, Kilifi County, Kenya"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Agoti","sequence":"additional","affiliation":[{"name":"KEMRI-Wellcome Trust Research Programme, Center for Geographic Medicine Research, Coast","place":["Kilifi, Kilifi County, Kenya"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Sande","sequence":"additional","affiliation":[{"name":"KEMRI-Wellcome Trust Research Programme, Center for Geographic Medicine Research, Coast","place":["Kilifi, Kilifi County, Kenya"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Bejon","sequence":"additional","affiliation":[{"name":"KEMRI-Wellcome Trust Research Programme, Center for Geographic Medicine Research, Coast","place":["Kilifi, Kilifi County, Kenya"]},{"name":"Nuffield Department of Medicine, Oxford University","place":["Oxford, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalan","family":"Bailey","sequence":"additional","affiliation":[{"name":"Viral Glycoproteins Group, The Pirbright Institute","place":["Pirbright, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George Mbugua","family":"Warimwe","sequence":"additional","affiliation":[{"name":"KEMRI-Wellcome Trust Research Programme, Center for Geographic Medicine Research, Coast","place":["Kilifi, Kilifi County, Kenya"]},{"name":"Nuffield Department of Medicine, Oxford University","place":["Oxford, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. Isabella","family":"Ochola-Oyier","sequence":"additional","affiliation":[{"name":"KEMRI-Wellcome Trust Research Programme, Center for Geographic Medicine Research, Coast","place":["Kilifi, Kilifi County, Kenya"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doreen","family":"Lugano","sequence":"additional","affiliation":[{"name":"KEMRI-Wellcome Trust Research Programme, Center for Geographic Medicine Research, Coast","place":["Kilifi, Kilifi County, Kenya"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven Ger","family":"Nyanjom","sequence":"additional","affiliation":[{"name":"Jomo Kenyatta University of Agriculture and Technology","place":["Nairobi, Kenya"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Nyagwange","sequence":"additional","affiliation":[{"name":"KEMRI-Wellcome Trust Research Programme, Center for Geographic Medicine Research, Coast","place":["Kilifi, Kilifi County, Kenya"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1128\/mbio.02901-25","article-title":"Antibody responses to SARS-CoV-2 variants LP.8.1, LF.7.1, NB.1.8.1, XFG, and BA.3.2 following KP.2 monovalent mRNA vaccination","volume":"17","author":"Abbad","year":"2026","journal-title":"mBio"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e463","DOI":"10.1016\/S1473-3099(25)00071-4","article-title":"Rethinking the evidence on COVID-19 in Africa","volume":"25","author":"Bejon","year":"2025","journal-title":"Lancet Infect. Dis."},{"key":"B3","unstructured":"Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing\n          \n          \n            \n              Benjaminit\n              Y.\n            \n            \n              Hochberg\n              Y.\n            \n          \n          \n          1995"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-020-0191-1","article-title":"Immune response in COVID-19: addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2","volume":"5","author":"Catanzaro","year":"2020","journal-title":"Signal. Transduct Target Ther."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/S1473-3099(23)00379-1","article-title":"Effectiveness of monovalent and bivalent COVID-19 vaccines","volume":"23","author":"Cerqueira-Silva","year":"2023","journal-title":"Lancet Infect. Dis."},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.113522","article-title":"Omicron variant (B.1.1.529) and its sublineages: What do we know so far amid the emergence of recombinant variants of SARS-CoV-2","volume":"154","author":"Dhawan","year":"2022","journal-title":"Biomedicine Pharmacotherapy"},{"key":"B7","unstructured":"Morbidity and Mortality Weekly Report COVID-19 Vaccination Coverage-World Health Organization African Region, 2021-2023\n          \n          \n            \n              Doshi\n              R. H.\n            \n            \n              Nsasiirwe\n              S.\n            \n            \n              Dahlke\n              M.\n            \n          \n          \n          2021"},{"key":"B8","article-title":"EMA recommendation to update the antigenic composition of authorised COVID-19 vaccines for 2026-2027 (EMA\/127531\/2026)","year":"2026"},{"key":"B9","unstructured":"European Medicine Agency Recommends Updating COVID-19 Vaccines to Target XFG Variant\n          \n          \n          \n          2026"},{"key":"B10","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.vacun.2022.06.002","article-title":"Multivalent vaccines against new SARS-CoV-2 hybrid variants","volume":"24","author":"Ghazvini","year":"2023","journal-title":"Vacunas"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e374","DOI":"10.1016\/S1473-3099(25)00308-1","article-title":"Antigenic and virological characteristics of SARS-CoV-2 variants BA.3.2, XFG, and NB.1.8.1","volume":"25","author":"Guo","year":"2025","journal-title":"Lancet Infect. Dis."},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(24)00731-X","article-title":"Virological characteristics of the SARS-CoV-2 XEC variant","volume":"24","author":"Kaku","year":"2024","journal-title":"Lancet Infect. Dis."},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(23)00813-7","article-title":"Virological characteristics of the SARS-CoV-2 JN.1 variant","volume":"24","author":"Kaku","year":"2024","journal-title":"Lancet Infect. Dis."},{"key":"B14","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1038\/nmeth.4285","article-title":"Fast model selection for accurate phylogenetic estimates","volume":"14","author":"Kalyaanamoorthy","year":"2017","journal-title":"Nat. Methods"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","article-title":"Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection","volume":"27","author":"Khoury","year":"2021","journal-title":"Nat. Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"5556","DOI":"10.1016\/j.csbj.2021.10.004","article-title":"N-terminal domain mutations of the spike protein are structurally implicated in epitope recognition in emerging SARS-CoV-2 strains","volume":"19","author":"Klinakis","year":"2021","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"B17","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s44263-025-00201-6","article-title":"Genomic and clinical epidemiology of SARS-CoV-2 in coastal Kenya: insights into variant circulation, reinfection, and multiple lineage importations during a post-pandemic wave","volume":"3","author":"Lambisia","year":"2025","journal-title":"BMC Glob. Public Health"},{"key":"B18","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1093\/ofid\/ofag084","article-title":"Longitudinal epidemiology and variant dynamics of SARS-CoV-2 in Coastal Kenya (2020\u20132025): clinical features and wave patterns","volume":"13","author":"Lambisia","year":"2026","journal-title":"Open Forum Infect. Dis."},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1101\/2025.11.10.25338449","article-title":"Low transmission of the globally dominant recombinant SARS-coV-2 XFG variant in Kenya, may-july 2025","author":"Lambisia","year":"2025"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2022.2034457","article-title":"Low coverage of COVID-19 vaccines in Africa: current evidence and the way forward","volume":"18","author":"Lawal","year":"2022","journal-title":"Hum. Vaccin. Immunother."},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1101\/2024.11.12.623078","article-title":"Immune evasion, cell-cell fusion, and spike stability of the SARS-coV-2 XEC variant: role of glycosylation mutations at the N-terminal domain","author":"Li","year":"2024"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.114520","article-title":"Neutralization escape, infectivity, and membrane fusion of JN.1-derived SARS-CoV-2 SLip, FLiRT, and KP.2 variants","volume":"43","author":"Li","year":"2024","journal-title":"Cell Rep."},{"key":"B23","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41586-022-04465-y","article-title":"Vaccines elicit highly conserved cellular immunity to SARS-CoV-2 Omicron","volume":"603","author":"Liu","year":"2022","journal-title":"Nature"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e128","DOI":"10.1016\/S1473-3099(25)00015-5","article-title":"Virological and antigenic characteristics of SARS-CoV-2 variants LF.7.2.1, NP.1, and LP.8.1","volume":"25","author":"Liu","year":"2025","journal-title":"Lancet Infect. Dis."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1186\/s12879-024-10367-3","article-title":"Evaluation of population immunity against SARS-CoV-2 variants, EG.5.1, FY.4, BA.2.86, JN.1, JN.1.4, and KP.3.1.1 using samples from two health demographic surveillance systems in Kenya","volume":"24","author":"Lugano","year":"2024","journal-title":"BMC Infect. Dis."},{"key":"B26","doi-asserted-by":"publisher","first-page":"e453","DOI":"10.1016\/S1473-3099(23)00815-0","article-title":"Persistent SARS-CoV-2 infection: significance and implications","volume":"24","author":"Machkovech","year":"2024","journal-title":"Lancet Infect. Dis."},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2025.116440","article-title":"Antibody evasion and receptor binding of SARS-CoV-2 LP.8.1.1, NB.1.8.1, XFG, and related subvariants","volume":"44","author":"Mellis","year":"2025","journal-title":"Cell Rep."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1093\/molbev\/msaa015","article-title":"IQ-TREE 2: new models and efficient methods for phylogenetic inference in the genomic era","volume":"37","author":"Minh","year":"2020","journal-title":"Mol. Biol. Evol."},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1093\/ve\/veaf035","article-title":"Emergence and transmission dynamics of the FY.4 Omicron variant in Kenya","volume":"11","author":"Musundi","year":"2025","journal-title":"Virus Evol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ijid.2022.11.041","article-title":"Serum immunoglobulin G and mucosal immunoglobulin A antibodies from prepandemic samples collected in Kilifi, Kenya, neutralize SARS-CoV-2 in vitro","volume":"127","author":"Nyagwange","year":"2023","journal-title":"Int. J. Infect. Dis."},{"key":"B31","doi-asserted-by":"publisher","first-page":"69","DOI":"10.12688\/wellcomeopenres.17661.1","article-title":"Epidemiology of COVID-19 infections on routine polymerase chain reaction (PCR) and serology testing in Coastal Kenya","volume":"7","author":"Nyagwange","year":"2022","journal-title":"Wellcome Open Res."},{"key":"B32","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1038\/s41392-022-00992-2","article-title":"Tracking SARS-CoV-2 Omicron diverse spike gene mutations identifies multiple inter-variant recombination events","volume":"7","author":"Ou","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"B33","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1038\/s41467-024-46490-7","article-title":"Distinct evolution of SARS-CoV-2 Omicron XBB and BA.2.86\/JN.1 lineages combining increased fitness and antibody evasion","volume":"15","author":"Planas","year":"2024","journal-title":"Nat. Commun."},{"key":"B34","doi-asserted-by":"crossref","DOI":"10.17504\/protocols.io.bp2l6n26rgqe\/v4","volume-title":"ARTIC SARS-Cov-2 Sequencing Protocol V4 (LSK114)","author":"Quick","year":"2024"},{"key":"B35","doi-asserted-by":"publisher","first-page":"37","DOI":"10.2450\/2008.0001-08","article-title":"The statistical analysis of immunohaematological data","volume":"6","author":"Reverberi","year":"2008","journal-title":"Blood Transfusion"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1126\/science.abm0811","article-title":"Heterologous infection and vaccination shapes immunity against SARS-CoV-2 variants","author":"Reynolds","year":"2022","journal-title":"Science"},{"key":"B37","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/s41591-022-02092-8","article-title":"Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant in mice","volume":"29","author":"Scheaffer","year":"2023","journal-title":"Nat. Med."},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.830527","article-title":"Omicron: A heavily mutated SARS-CoV-2 variant exhibits stronger binding to ACE2 and potently escapes approved COVID-19 therapeutic antibodies","volume":"12","author":"Shah","year":"2022","journal-title":"Front. Immunol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"e462","DOI":"10.1016\/S1473-3099(23)00588-1","article-title":"Sensitivity of the SARS-CoV-2 BA.2.86 variant to prevailing neutralising antibody responses","volume":"23","author":"Sheward","year":"2023","journal-title":"Lancet Infect. Dis."},{"key":"B40","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/s41392-023-01449-w","article-title":"Evolutionary characteristics of SARS-CoV-2 Omicron subvariants adapted to the host","volume":"8","author":"Tang","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2025.1714899","article-title":"Molecular and seroepidemiology of SARS-CoV-2 among influenza-like illness and severe acute respiratory illness cases in selected health facilities in Ethiopia","volume":"13","author":"Tayachew","year":"2026","journal-title":"Front. Public Health"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1128\/msphere.00758-23","article-title":"Immune imprinting of SARS-CoV-2 responses: changing first immune impressions","volume":"9","author":"Torresi","year":"2024","journal-title":"mSphere"},{"key":"B43","volume-title":"COVID-19 Vaccines (2025\u20132026 Formula) for Use in the United States Beginning in Fall 2025","year":""},{"key":"B44","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/s41586-022-05053-w","article-title":"Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5","volume":"608","author":"Wang","year":"2022","journal-title":"Nature"},{"key":"B45","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.cell.2022.12.018","article-title":"Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants","volume":"186","author":"Wang","year":"2023","journal-title":"Cell"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2024.2402880","article-title":"Recurrent SARS-CoV-2 spike mutations confer growth advantages to select JN.1 sublineages","volume":"13","author":"Wang","year":"2024","journal-title":"Emerg. Microbes Infect."},{"key":"B47","unstructured":"Who Tag-Co-Vac, 2025\n          \n          \n          \n          2025"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1126\/science.adj0070","article-title":"Mapping SARS-CoV-2 antigenic relationships and serological responses","volume":"382","author":"Wilks","year":"2023","journal-title":"Science"},{"key":"B49","unstructured":"Probable Inference, the Law of Succession, and Statistical Inference\n          \n          \n            \n              Wilson\n              E. B.\n            \n          \n          \n          1927"},{"key":"B50","unstructured":"Statement on the Fifteenth Meeting of the IHR (2005) Emergency Committee on the COVID-19 Pandemic\n          \n          \n          \n          2023"},{"key":"B51","unstructured":"Statement on the Antigen Composition of COVID-19 Vaccines\n          \n          \n          \n          2026"},{"key":"B52","unstructured":"Updated Risk Evaluation of JN.1\n          \n          \n          \n          2024"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-5247(22)00335-4","article-title":"Omicron sublineage recombinant XBB evades neutralising antibodies in recipients of BNT162b2 or CoronaVac vaccines","volume":"4","author":"Zhang","year":"2023","journal-title":"Lancet Microbe"}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2026.1910106\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T05:21:35Z","timestamp":1788412895000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2026.1910106\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,3]]},"references-count":53,"alternative-id":["10.3389\/fcimb.2026.1910106"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2026.1910106","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,3]]},"article-number":"1910106"}}